Vimarsana
Biggest News Aggregation in the World

Page 13 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Zacks: Analysts Expect Editas Medicine, Inc. (NASDAQ:EDIT) Will Announce Earnings of -$0.84 Per Share - Vimarsana News

Zacks: Analysts Expect Editas Medicine, Inc. (NASDAQ:EDIT) Will Announce Earnings of -$0.84 Per Share

Brokerages predict that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post earnings of ($0.84) per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.72). Editas Medicine posted earnings of ($0.81) per share in […]

Brokerages Expect Editas Medicine, Inc. (NASDAQ:EDIT) to Post -$0.81 EPS - Vimarsana News

Brokerages Expect Editas Medicine, Inc. (NASDAQ:EDIT) to Post -$0.81 EPS

Analysts expect that Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) will post earnings of ($0.81) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Editas Medicine’s earnings. The lowest EPS estimate is ($0.91) and the highest is ($0.75). Editas Medicine reported earnings of ($0.86) per share during the same […]

Editas Medicine Appoints Gilmore O'Neill as Chief Executive - Vimarsana News

Editas Medicine Appoints Gilmore O'Neill as Chief Executive

James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading...

Editas Medicine Announces Dosing of First Pediatric Patient - Vimarsana News

Editas Medicine Announces Dosing of First Pediatric Patient

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of...

Zacks: Analysts Anticipate Editas Medicine, Inc. (NASDAQ:EDIT) Will Post Quarterly Sales of $4.60 Million - Vimarsana News

Zacks: Analysts Anticipate Editas Medicine, Inc. (NASDAQ:EDIT) Will Post Quarterly Sales of $4.60 Million

Wall Street analysts expect Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) to report $4.60 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Editas Medicine’s earnings. The highest sales estimate is $5.00 million and the lowest is $3.80 million. Editas Medicine reported sales of $6.50 million in the […]